This trial has been completed.

Condition supraventricular tachycardia
Treatment no intervention
Sponsor Lakeland Health
Start date January 2012
End date July 2016
Trial size 63 participants
Trial identifier NCT02810561, LH01


The goal of this study is twofold. First the investigators would like to determine the trajectory of troponin leaks; if it can be shown that the participants who have only minimal elevations of their repeat troponin universally decrease on the 3rd level then future patients may see significantly improved length of stay. Second, given conflicting results in the literature, the investigators would like to determine if elevated troponin levels correlate to later cardiovascular complications. These complications will be defined as Death, Myocardial Infarction, Cardiovascular intervention (such as coronary artery stenting or bypass). As the investigator is a single hospital system in this county it is uniquely positioned to be able to review this retrospectively.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

Troponin-I Level
time frame: 6 hours after initial EKG

Secondary Outcomes

Death/ Need for Cardiac Stent Placement or Coronary Bypass Artery Graft
time frame: 6 months

Eligibility Criteria

All participants of any age.

Inclusion Criteria: - Supraventricular Tachycardia with troponin elevation Exclusion Criteria: - Other cardiac arrhythmias or conditions with increased troponin

Additional Information

Official title Time Course and the Significance of Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)
Principal investigator Matthew Hysell, MD
Description The investigators therefore propose retrospectively studying participants diagnosed with Supraventricular Tachycardia who had troponin(s) checked in the ED between January 1, 2012 and May 31, 2016 to allow a minimum of a year follow-up for our combined endpoint. The investigators will record the participants troponin value(s) in addition to the age, sex, race, heart rate, creatinine value. The investigators will compare the participants with positive troponins (and hopefully participants with strongly positive troponins) with those who are negative for troponin for presence of the combined end point via chart review.
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Lakeland Health.